Compare ASUR & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | MDWD |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 214.9M |
| IPO Year | 1996 | 2013 |
| Metric | ASUR | MDWD |
|---|---|---|
| Price | $9.27 | $16.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $14.33 | ★ $36.00 |
| AVG Volume (30 Days) | 68.6K | ★ 91.0K |
| Earning Date | 04-30-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $16.33 | $48.92 |
| Revenue Next Year | $9.20 | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $14.90 |
| 52 Week High | $11.47 | $22.51 |
| Indicator | ASUR | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 45.32 |
| Support Level | $7.83 | $14.90 |
| Resistance Level | $9.89 | $18.49 |
| Average True Range (ATR) | 0.40 | 0.63 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 68.06 | 20.41 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.